ライフサイエンスコーパス: neurocognitive disorder

1 es, which are dysregulated in HIV-associated neurocognitive disorder.

2 ators of neurodegeneration in HIV-associated neurocognitive disorders.

3 iates a process that causes HIV-1-associated neurocognitive disorders.

4 al nervous system HIV infection and clinical neurocognitive disorders.

5 may offer protection against HIV-associated neurocognitive disorders.

6 adaptive immune responses to HIV-associated neurocognitive disorders.

7 ed as a risk determinant of HIV-1-associated neurocognitive disorders.

8 with HIV, and may exacerbate HIV-associated neurocognitive disorders.

9 ls, approximately 60% develop HIV-associated neurocognitive disorders.

10 the brain early in infection and can lead to neurocognitive disorders.

11 nefit for a CNS-T strategy in HIV-associated neurocognitive disorders.

12 nd oxidative stress has been associated with neurocognitive disorders.

13 role in the pathogenesis of HIV-1-associated neurocognitive disorders.

14 n of neurological function in HIV-associated neurocognitive disorders.

15 nosis and assessment of neuropsychiatric and neurocognitive disorders.

16 nodeficiency Virus type 1 (HIV-1)-associated neurocognitive disorders.

17 omenon that could lead to the development of neurocognitive disorders.

18 ndromes collectively known as HIV-associated neurocognitive disorders.

19 py of Alzheimer's disease and possibly other neurocognitive disorders.

20 ial therapeutic targets for HIV-1-associated neurocognitive disorders.

21 l as in the pathogenesis of HIV-1-associated neurocognitive disorders.

22 roved design of therapies for HIV-associated neurocognitive disorders.

23 reatment can be developed for HIV-associated neurocognitive disorders.

24 tribute to the development of HIV-associated neurocognitive disorders.

25 an effect has been found for HIV-associated neurocognitive disorders.

26 s 30.7% (HIV-associated dementia, 3.2%; mild neurocognitive disorder, 12.6%; and asymptomatic neuroco

27 ocognitive disorder, 12.6%; and asymptomatic neurocognitive disorder, 15.0%; HIV- group: 13.9%; P = .

28 e combination antiretroviral therapy (cART), neurocognitive disorders afflict 30-50% of HIV-infected

29 sorders to include complex diseases, such as neurocognitive disorders and cancer predisposition.

30 injury is thought to underlie HIV-associated neurocognitive disorders and contributes to exaggerated

31 Despite the possible overlap between neurocognitive disorders and glaucoma in older individua

32 d had a higher prevalence of CVS plus (CVS + neurocognitive disorders) as compared to adult-onset CVS

33 icating the Toll-like receptors (TLR) in the neurocognitive disorders associated with NeuroAIDS in th

34 nflammatory diseases, such as HIV-associated neurocognitive disorders, cancer, and atherosclerosis.

35 ave shown that HIV-infected patients develop neurocognitive disorders characterized by neuronal dysfu

36 ral HIV DNA reservoir in the pathogenesis of neurocognitive disorder during suppressive ART.

37 HIV-associated neurocognitive disorder (HAND) affects approximately hal

38 HIV-associated neurocognitive disorder (HAND) affects approximately hal

39 een HIV-1 RNA discordance and HIV-associated neurocognitive disorder (HAND) may reflect compartmental

40 of HIV+ individuals; however, HIV-associated neurocognitive disorder (HAND) occurrence is increasing

41 tes with cognitive decline in HIV-associated neurocognitive disorder (HAND) patients.

42 Milder forms of HIV-associated neurocognitive disorder (HAND) remain common in HIV-infe

43 uman immunodeficiency virus (HIV)-associated neurocognitive disorder (HAND) remain unanswered.

44 nodeficiency virus type-1 (HIV-1)-associated neurocognitive disorder (HAND) remains an important neur

45 long with its contribution to HIV-associated neurocognitive disorder (HAND) remains ill-defined.

46 mpairment (GDS >/= 0.50), and HIV-associated neurocognitive disorder (HAND) using international crite

47 ins of individuals exhibiting HIV-associated neurocognitive disorder (HAND), likely driven by neuroin

48 tes with cognitive decline in HIV-associated neurocognitive disorder (HAND).

49 by the rising incidence of HIV-1-associated neurocognitive disorders (HAND) among infected individua

50 rent non-infectious models of HIV-associated neurocognitive disorders (HAND) and reveals a precise co

51 clades differentially induce HIV-associated neurocognitive disorders (HAND) and substance abuse is k

52 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) are not routinely assess

53 at plays an important role in HIV-associated neurocognitive disorders (HAND) by disrupting neurotrans

54 lia play a pathogenic role in HIV-associated neurocognitive disorders (HAND) by instigating primary d

55 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) can show variable clinic

56 he most challenging issues in HIV-associated neurocognitive disorders (HAND) caused by HIV-1 virotoxi

57 discusses current concepts of HIV-associated neurocognitive disorders (HAND) in the era of antiretrov

58 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) is a significant source

59 HIV-associated neurocognitive disorders (HAND) is characterized by deve

60 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) reflect the spectrum of

61 IV infection is now possible, HIV-associated neurocognitive disorders (HAND) remain intractable.

62 the pathophysiology of these HIV-associated neurocognitive disorders (HAND) remains unresolved.

63 HIV-associated neurocognitive disorders (HAND) represent a spectrum dis

64 vation better correlates with HIV-associated neurocognitive disorders (HAND) than productive HIV-1 in

65 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HAND) that result from HIV inf

66 The continued prevalence of HIV-associated neurocognitive disorders (HAND) underscores the need for

67 he neurodegenerative syndrome HIV-associated neurocognitive disorders (HAND), for which there is no s

68 uman immunodeficiency virus (HIV) associated neurocognitive disorders (HAND), including memory dysfun

69 ted individuals still develop HIV-Associated Neurocognitive Disorders (HAND), indicating that host in

70 process, now referred to as HIV-1-associated neurocognitive disorders (HAND), provides a range of mol

71 of Parkinson's disease and HIV-1 associated neurocognitive disorders (HAND), requiring an inhibitor

72 ate abusers and patients with HIV-associated neurocognitive disorders (HAND), which is typically exac

73 iduals frequently suffer from HIV-associated neurocognitive disorders (HAND), with about 30% of AIDS

74 he most prevalent features of HIV-associated neurocognitive disorders (HAND), yet their origins are u

75 ribute to the pathogenesis of HIV-associated neurocognitive disorders (HAND).

76 licated in the development of HIV-associated neurocognitive disorders (HAND).

77 f HIV-infected people exhibit HIV-associated neurocognitive disorders (HAND).

78 immunodeficiency virus 1 (HIV-1)-associated neurocognitive disorders (HAND).

79 the main underlying causes of HIV-associated neurocognitive disorders (HAND).

80 HIV-positive individuals with HIV-associated neurocognitive disorders (HAND).

81 tes toward the development of HIV-associated neurocognitive disorders (HAND).

82 immunodeficiency virus-1 (HIV-1)-associated neurocognitive disorders (HAND).

83 ies continue, which include HIV-1-associated neurocognitive disorders (HAND).

84 uman immunodeficiency virus (HIV)-associated neurocognitive disorders (HANDs) remain among the most c

85 owever, the role of nAChRs in HIV-associated neurocognitive disorder has not been investigated.

86 ber variants (CNVs) are associated with many neurocognitive disorders; however, these events are typi

87 escribe the manifestations of HIV-associated neurocognitive disorder in the era of effective HIV ther

88 a neuroinflammatory response and subsequent neurocognitive disorders in adulthood.

89 pathological presentation of HIV-associated neurocognitive disorders in the post-ARV era.

90 ing or brain DHA are associated with various neurocognitive disorders including Alzheimer's disease (

91 f synaptic connections is a hallmark of many neurocognitive disorders, including HAND.

92 munodeficiency Virus type-1 (HIV)-associated neurocognitive disorder is characterized by recruitment

93 and prevention strategies for HIV-associated neurocognitive disorders likely need to be tailored base

94 ly being used in clinical practice for minor neurocognitive disorder (MND) as well as HAD, despite un

95 t for preventing and treating HIV-associated neurocognitive disorder; nevertheless, clear cerebrospin

96 eted for regular screening for HIV-associate neurocognitive disorder, particularly with tests referab

97 uman immunodeficiency virus (HIV)-associated neurocognitive disorders persist despite suppressive ant

98 Neurocognitive disorders remain common among human immun

99 HIV-associated neurocognitive disorders remain prevalent among HIV type

100 ly relevant HIV-associated dementia and mild neurocognitive disorder sensitivity was 100% and specifi

101 t cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with altera

102 t cognitive deficits in neuropsychiatric and neurocognitive disorders that are associated with altera

103 uman immunodeficiency virus (HIV)-associated neurocognitive disorders, we examined persons with acqui

104 uman immunodeficiency virus (HIV)-associated neurocognitive disorders, we quantified HIV type 1 (HIV-

105 uding Alzheimer's disease and HIV-associated neurocognitive disorders where APP misprocessing to amyl

106 g users have an increased risk of developing neurocognitive disorders with increased progression to d